ClinicalTrials.gg

Program

cp-547632

Also written as “PAN-90806 Ophthalmic Solution”, “CP-547,632” and “PAN-90806 Ophthalmic Suspension”.

Its studies are mostly in Macular Degeneration · Diabetic Retinopathy · Lung Neoplasms · Ovarian Neoplasms, led by 3 companies.

Furthest: phase 2, since Mar 14, 20186 company-led studies, 1 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PanOptica30 open or runningphase 2since Mar 14, 2018Dec 20, 2013none ahead
Pfizer20 open or runningphase 2since Dec 22, 2003Dec 22, 2003none ahead
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical11 open or runningphase 1since Jun 22, 2026Jun 22, 2026Dec 30, 2026phase 1 · NCT07764965

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2003First studies: 2 phase 2 studiesNew to PfizerPfizer · NCT00074867, NCT00074854
  2. Dec 20, 2013PanOptica's first study: phase 1 study in Macular DegenerationNew to PanOpticaPanOptica · NCT02022540 · 50 enrolled · United States
  3. Jun 13, 2015Phase 1 study in Diabetic RetinopathyPanOptica · NCT02475109 · 10 enrolled · United States
  4. Mar 14, 2018Phase 2 study in Macular DegenerationPanOptica · NCT03479372 · 51 enrolled · United States, Czechia, Hungary and more
  5. Jun 22, 2026Zhaoke (Guangzhou) Ophthalmology Pharmaceutical's first study: phase 1 study in Macular DegenerationNew to Zhaoke (Guangzhou) Ophthalmology PharmaceuticalZhaoke (Guangzhou) Ophthalmology Pharmaceutical · NCT07764965 · 20 planned

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Macular DegenerationZhaoke (Guangzhou) Ophthalmology Pharmaceutical · NCT07764965

TargetBeta

KDR →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
apatinibruleJiangsu HengRui Medicinephase 347
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07764965Macular Degeneration1Not yet recruitingZhaoke (Guangzhou) Ophthalmology PharmaceuticalDec 30, 202620
NCT03479372Macular Degeneration · United States, Czechia, Hungary and more2CompletedPanOpticaMay 27, 201951
NCT02475109Diabetic Retinopathy · United States1CompletedPanOpticaMay 201610
NCT02022540Macular Degeneration · United States1CompletedPanOpticaMar 201650
NCT00074867Ovarian Neoplasms · United States, Canada2CompletedPfizer29
NCT00074854Lung Neoplasms · United States2CompletedPfizer87

How it is read

Names in the registry

  • “PAN-90806 Ophthalmic Solution”, 3 entries
  • “CP-547,632”, 2 entries
  • “PAN-90806 Ophthalmic Suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.